DE

The Future Map · technological enabler · active

Gene Editing

Maturity

4 / 5

Basis, source, vintage

Approved therapies in market; agricultural applications advancing; delivery, cost and governance are the binding constraints.

Source: Regulatory approval records for CRISPR-based therapies (2024–2026)

What it is

Making targeted changes to a genome — CRISPR and its successors — in medicine, agriculture and industrial biology.

What it does

It moves biology from reading to writing. The first approved therapies exist, which makes this one of the few frontier technologies in this Compendium with a delivered clinical outcome.

Common misconception

That the constraint is technical. Delivery to the right cells, cost per patient, and the governance of heritable edits are each further from resolution than the editing itself.

Steepens

A megatrend runs at the pace of its shallowest enabler. Marginal links are shown but never set the pace.

What would change its gradient

Shares megatrends with

In the book

Why the Future Arrives Unevenly — Ch. 7 — The Inversion of the Population Pyramid · Ch. 12 — Reading the Ramp · Ch. 14 — How Hype Is Manufactured

Sources


See it in the map →

Cite this entry

Talin, B. (2026). Gene Editing. The Future Map, dataset v0.4.0 (2026-09-07). https://futuremap.talin.digital/e/gene-editing/

Machine view: This entry as Markdown · The whole map as JSON

Updated 2026-09-02.